IFNalpha Kinoid Continues to be Studied for Treatment of Systemic Lupus Erythematosus
Pharmaceutical companies, Neovacs and Centurion Pharma, continue joint development and investigation of IFNalpha Kinoid for people with systemic lupus erythematosus (SLE). The vaccine has shown to block the pro-inflammatory molecule IFN-alpha that activates autoimmune response and is overproduced in people with lupus. The U.S. Food and Drug Administration (FDA) granted a Fast Track designation to the therapy in 2016, which is also being developed for dermatomyositis and type 1 diabetes. Continue to follow the Lupus Foundation of America for updates on IFNalpha Kinoid.